Moderna(MRNA)
icon
搜索文档
mRNA Cancer Vaccines and Therapeutics Research Report 2024 with Long-term Forecasts to 2028 and 2033: Personalized Medicine and Multivalent mRNA Vaccines Lead the Way
GlobeNewswire News Room· 2024-10-14 23:48
文章核心观点 - mRNA癌症疫苗和治疗市场规模近年来增长迅速,预计未来几年将继续保持快速增长 [1][2][3] - 市场增长的主要驱动因素包括生活方式变化导致的医疗需求增加、医疗研发投资支持增加、监管环境有利于创新、成熟的医疗基础设施以及新疗法管线的不断发展 [2][3] - 未来增长将得益于临床试验的有希望结果、mRNA技术在癌症治疗中的认知和接受度提高、巨大的未满足医疗需求、可能带来的更好的患者预后以及现成治疗方案的前景 [3] - 主要趋势包括拓展新的治疗领域、采用个性化医疗方法、mRNA递送系统的进步、针对多个抗原的多价mRNA疫苗开发以及人工智能和机器学习在优化mRNA设计中的应用 [3] 行业概况 - 癌症发病率上升将推动mRNA癌症疫苗和治疗市场的增长 [4] - mRNA癌症疫苗和治疗在癌症治疗中发挥关键作用,通过增强免疫系统识别和攻击癌细胞来提高治疗效果和患者预后 [4] 公司概况 - 行业内领先公司专注于开发创新的mRNA癌症疫苗等治疗方案,以提高疗效并满足不断增长的需求 [5][6] - 主要公司包括辉瑞、默克、拜耳、诺华、赛诺菲、阿斯利康、葛兰素史克、罗氏、礼来、莫德纳、BioNTech、再生元等 [6]
Coinbase, Nike And Moderna Are Among Top 11 Large Cap Losers Last Week (Sept 30-Oct 4): Are The Others In Your Portfolio?
Benzinga· 2024-10-07 01:13
很抱歉,这篇新闻文章没有提供足够的信息供我进行深入的行业和公司研究分析。这篇文章主要列举了一些表现较差的大盘股,但并没有详细介绍这些公司的具体情况和行业动态。我无法从中提取出有价值的关键要点。如果您有其他更详细的公司或行业相关新闻,我很乐意进行深入分析,为您提供专业的研究意见。
MRNA DEADLINE TUESDAY: ROSEN, A LEADING LAW FIRM, Encourages Moderna, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important October 8 Deadline in Securities Class Action – MRNA
GlobeNewswire News Room· 2024-10-06 23:13
文章核心观点 - 根据诉讼,在整个Class Period期间,被告做出了虚假和/或误导性陈述,和/或未能披露:(1)mRNA-1345,一种旨在保护60岁及以上成人免受RSV感染引起的下呼吸道疾病的mRNA呼吸道合胞病毒(RSV)疫苗,其疗效低于被告所宣称的水平[3] - 因此,mRNA-1345的临床和/或商业前景被夸大了[3] - 当真实情况进入市场时,投资者遭受损失[3] 根据相关目录分别进行总结 公司概况 - Moderna Inc.(纳斯达克代码:MRNA)是一家生物技术公司,专注于开发mRNA疫苗和治疗[无] 行业概况 - 公司主要从事呼吸道合胞病毒(RSV)疫苗的研发[3] 本次诉讼 - 根据诉讼,Moderna公司在2023年1月18日至2024年6月25日期间(Class Period)做出了虚假和/或误导性陈述[3] - 这些陈述涉及公司的mRNA-1345 RSV疫苗的疗效低于预期[3] - 这导致公司的公开声明在所有相关时期都存在重大虚假和误导[3] - 当真实情况被披露时,投资者遭受损失[3]
MRNA Deadline: MRNA Investors Have Opportunity to Lead Moderna, Inc. Securities Fraud Lawsuit
Prnewswire· 2024-10-05 03:10
NEW YORK, Oct. 4, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Moderna, Inc. (NASDAQ: MRNA) between January 18, 2023 and June 25, 2024, both dates inclusive (the "Class Period"), of the important October 8, 2024 lead plaintiff deadline. So what: If you purchased Moderna securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. What to do next: ...
IMPORTANT MRNA DEADLINE: TOP RANKED ROSEN LAW FIRM Encourages Moderna, Inc. Investors to Secure Counsel Before Important October 8 Deadline in Securities Class Action – MRNA
GlobeNewswire News Room· 2024-10-04 04:41
NEW YORK, Oct. 03, 2024 (GLOBE NEWSWIRE) -- __________________ WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Moderna, Inc. (NASDAQ: MRNA) between January 18, 2023 and June 25, 2024, both dates inclusive (the "Class Period"), of the important October 8, 2024 lead plaintiff deadline. SO WHAT: If you purchased Moderna securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee a ...
MRNA Begins Dosing in Pivotal Study on Norovirus Vaccine
ZACKS· 2024-10-01 23:11
Moderna, Inc. (MRNA) announced the dosing of the first participant in the phase III Nova 301 study, which is evaluating its investigational mRNA norovirus vaccine candidate, mRNA-1403, in the United States. The randomized, placebo-controlled phase III study will evaluate the safety, efficacy and immunogenicity of mRNA-1403 to prevent moderate-to-severe acute gastroenteritis caused by norovirus. Recruitment of participants in the pivotal Nova 301 study across the world has also begun. Shares of Moderna have ...
Dr. Robert Langer, Co-Founder of Moderna, Joins Scientific Advisory Board of Klotho Neurosciences, Inc. (KLTO)
GlobeNewswire News Room· 2024-09-30 08:30
NEW YORK, Sept. 29, 2024 (GLOBE NEWSWIRE) -- Klotho Neurosciences, Inc. (NASDAQ: KLTO), a cutting-edge biotechnology company focused on developing innovative therapies for neurodegenerative diseases and promoting healthy longevity, is proud to announce that Dr. Robert Langer, co-founder of Moderna, has joined its Scientific Advisory Board. In addition to lending his world-class scientific expertise to guide the company's strategic direction, this also signals Dr. Langer's strong belief in the company's miss ...
ROSEN, LEADING INVESTOR COUNSEL, Encourages Moderna, Inc. Investors to Secure Counsel Before Important October 8 Deadline in Securities Class Action – MRNA
GlobeNewswire News Room· 2024-09-28 05:19
NEW YORK, Sept. 27, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Moderna, Inc. (NASDAQ: MRNA) between January 18, 2023 and June 25, 2024, both dates inclusive (the "Class Period"), of the important October 8, 2024 lead plaintiff deadline. SO WHAT: If you purchased Moderna securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT T ...
Repair Biotechnologies and Genevant Sciences to Collaborate to Develop mRNA-LNP Therapy with First-in-Class Potential to Turn Back Atherosclerosis
GlobeNewswire News Room· 2024-09-26 20:00
SYRACUSE, New York, VANCOUVER, British Columbia, and BASEL, Switzerland, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Repair Biotechnologies, a biotechnology company developing first-in-class therapies capable of rapidly regressing atherosclerotic plaque, and Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust and expansive lipid nanoparticle (LNP) patent portfolio, today announced they have entered into a collaboration and nonexclusive license agreement to combine Repai ...
Shareholders that lost money on Moderna, Inc.(MRNA) Urged to Join Class Action - Contact The Gross Law Firm to Learn More
Prnewswire· 2024-09-26 17:45
NEW YORK, Sept. 26, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Moderna, Inc. (NASDAQ: MRNA). Shareholders who purchased shares of MRNA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/moderna-loss-submission-form/?id=105022&from=4 CLASS PERIOD: January 18, 2023 to June 2 ...